Literature DB >> 7909417

Difference in cytotoxicity of paclitaxel against neoplastic and normal cells.

H Matsuoka1, M Furusawa, H Tomoda, Y Seo.   

Abstract

The difference in growth response between neoplastic and contact-sensitive normal cells was investigated by cell growth curve, colony forming efficiency and flow cytometric analysis. Neoplastic cells (MKN-28, MKN-45, and MCF-7), treated with paclitaxel at a concentration of 0.01 mM, showed growth inhibition, low colony-forming efficiency and a prolonged G2+M phase accumulation. Normal cells (Balb/c 3T3 cells and human fibroblasts originating from stomach cancer tissue), treated with paclitaxel at a concentration of less than 0.5 microM, showed no growth inhibition and no decrease in colony-forming efficiency. Normal cells treated with 1 microM of paclitaxel showed low accumulation in G2+M phases. The results show that paclitaxel at concentrations ranging from 0.01 to 0.5 microM had a cytotoxic effect against neoplastic cells but not against normal cells, such as fibroblasts around the cancer cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7909417

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  7 in total

1.  Effect of Paullinia cupana on MCF-7 breast cancer cell response to chemotherapeutic drugs.

Authors:  Everaldo Hertz; Francine Carla Cadoná; Alencar Kolinski Machado; Verônica Azzolin; Sabrina Holmrich; Charles Assmann; Pauline Ledur; Euler Esteves Ribeiro; Olmiro Cezimbra DE Souza Filho; Maria Fernanda Mânica-Cattani; Ivana Beatrice Mânica DA Cruz
Journal:  Mol Clin Oncol       Date:  2014-10-08

2.  Paclitaxel interrupts TGF-beta1 signaling between gallbladder epithelial cells and myofibroblasts.

Authors:  Ho-Soon Choi; Christopher E Savard; Jae-Woon Choi; Rahul Kuver; Sum P Lee
Journal:  J Surg Res       Date:  2007-06-14       Impact factor: 2.192

3.  Enhanced anticancer activity of nanopreparation containing an MMP2-sensitive PEG-drug conjugate and cell-penetrating moiety.

Authors:  Lin Zhu; Tao Wang; Federico Perche; Anton Taigind; Vladimir P Torchilin
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-23       Impact factor: 11.205

Review 4.  Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer.

Authors:  C M Spencer; D Faulds
Journal:  Drugs       Date:  1994-11       Impact factor: 9.546

5.  Advantages of Using Paclitaxel in Combination with Oncolytic Adenovirus Utilizing RNA Destabilization Mechanism.

Authors:  Elora Hossain; Umma Habiba; Aya Yanagawa-Matsuda; Arefin Alam; Ishraque Ahmed; Mohammad Towfik Alam; Motoaki Yasuda; Fumihiro Higashino
Journal:  Cancers (Basel)       Date:  2020-05-12       Impact factor: 6.639

6.  Low-dose paclitaxel modulates tumour fibrosis in gastric cancer.

Authors:  Tomoya Tsukada; Sachio Fushida; Shinichi Harada; Shiroh Terai; Yasumichi Yagi; Jun Kinoshita; Katsunobu Oyama; Hidehiro Tajima; Itasu Ninomiya; Takashi Fujimura; Tetsuo Ohta
Journal:  Int J Oncol       Date:  2013-01-29       Impact factor: 5.650

7.  Chemodrug delivery using integrin-targeted PLGA-Chitosan nanoparticle for lung cancer therapy.

Authors:  Anish Babu; Narsireddy Amreddy; Ranganayaki Muralidharan; Gopal Pathuri; Hariprasad Gali; Allshine Chen; Yan D Zhao; Anupama Munshi; Rajagopal Ramesh
Journal:  Sci Rep       Date:  2017-11-07       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.